Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
  • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Definitions

• the object of the present invention is to provide novel compounds, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of peptic ulcer.
• the present invention also relates to the use of the compounds of the invention for inhibiting gastric acid secretion in mammals including man.
• the compounds of the invention may be used for prevention and treatment of gastrointestinal
• the compounds may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is
• the compounds of the invention may also be used for treatment or prophylaxis of inflammatory conditions in mammals, including man, especially those involving lysozymal enzymes .
• the invention also relates to pharmaceutical compositions containing the compounds of the invention, as active ingredient.
• the invention relates to processes for preparation of such new compounds and to the use of the active compounds for the preparation of pharmaceutical compositions for the medical use indicated above.
• the compounds of the invention will not block the uptake of iodine into the thyroid gland. It has earlie been disclosed in several lectures from the company, where the inventors are working that thyroid toxicity depends on if the compounds are lipophilic or not. The inventors have now unexpectedly found that it is not the lipophilicity that is the critical parameter.
• the claimed compounds which include rather hydrophilic compounds, do not give any thyroid toxic effect and have at the same time high acid secretion inhibitory effect.
• the compounds of the invention will also exhibit a high solubility and a high chemical stability in water.
• the compounds of the invention exhibit a high solubility and a high chemical stability in water.
• the compounds of the invention are therefore
• administration routes such as for instance oral and rectal administration.
• R 1 and R 2 which are different, is each methyl, -C(O)-
• the structural isomers of the compounds of the formula I may be used separately, or in equal or unequal mixtures.
• the compounds of the invention of the formula I have an asymmetric centre in the sulfur atom, i.e. exists as two optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are within the scope of the present invention.
• the compounds of the invention may be prepared
• Z is halogen such as CI, Br or I or a functionally equivalent group, with a compound of the formula III
• Q is a counter ion such as Na + , K + , Ag + or trialkylammonium.
• Salts obtained may be transformed to a therapeutically suitable salt such as sodium and potassium salts, by addition of NaOH and KOH, respectively or by ion exchange.
• a therapeutically suitable salt such as sodium and potassium salts, by addition of NaOH and KOH, respectively or by ion exchange.
• This oxidation may be carried out by using an oxidizing agent such as nitric acid, hydrogen peroxide,
• the oxidation may also be carried out enzymatically by using an oxidizing enzyme or microbiotically by using a suitable microorganism.
• the structural isomers obtained may be separated by means of crystallization or chromatography.
• Racemates obtained can be separated according to known methods, e.g. recrystallization from an optically active solvent.
• the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration. It is especially preferred to formulate the compounds of the invention into pharmaceutical formulations for parenteral administration.
• formulation contains a compound of the invention in combination with a pharmaceutically acceptable carrier.
• the carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule.
• the amount of active compounds is between 0.1- 95% by weight of the preparation, between 0.2-20% by weight in preparations for parenteral use and between 1 and 50% by weight in preparations for oral
• the compound selected may be mixed with a solid, powdered carrier, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable carrier, as well as with lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylenglycol waxes.
• a solid, powdered carrier such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable carrier, as well as with lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylenglycol waxes.
• lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylenglycol waxes.
• sulfoxides may be coated with an enteric coating, which protects the active compound from acid catalyzed degradation as long as the dosage form remains in the stomach.
• enteric coating is chosen among
• enteric-coating materials e.g. beeswax, shellac or anionic film-forming polymers such as cellulose acetate phtalate, hydroxypropyl- methylcellulose phthalate, partly methyl esterified methacrylic acid polymers and the like, if preferred in combination with a suitable plasticizer.
• enteric-coating materials e.g. beeswax, shellac or anionic film-forming polymers such as cellulose acetate phtalate, hydroxypropyl- methylcellulose phthalate, partly methyl esterified methacrylic acid polymers and the like, if preferred in combination with a suitable plasticizer.
• enteric-coating materials e.g. beeswax, shellac or anionic film-forming polymers such as cellulose acetate phtalate, hydroxypropyl- methylcellulose phthalate, partly methyl esterified methacrylic acid polymers and the like, if preferred in combination with a suitable plastic
• Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or
• Hard gelatine capsules may also be enteric-coated as described above.
• Hard gelatine capsules may contain granules or enteric-coated granules of the active compound.
• Hard gelatine capsules may also contain the active compound in combination with a solid powdered carrier such as lactose, saccharose, sorbitol,
• Dosage units for rectal administration may be prepared in the form of suppositories which contain the active substance mixed with a neutral fat base, or they may be prepared in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatine rectal capsules, or they may be prepared in the form of a ready-made micro enema, or they may be prepared in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
• Liquid preparation for oral administration may be prepared in the form of syrups or suspensions, e.g.
• solutions or suspensions containing from 0.2% to 20% by weight of the active ingredient and the remainder consisting of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and
• compositions may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agents.
• Liquid preparations for oral may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agents.
• administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.
• Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent, preferably in a concentration from 0.1% to 10% by weight.
• solutions may also contain stabilizing agents and/or buffering agents and may be manufactured in different unit dose ampoules or vials. Solutions for parenteral administration may also be prepared as a dry
• the typical daily dose of the active substance varies within a wide range and will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 500 mg per day of active substance.
• Example 1 Preparation of phosphoric acid, [5-acetyl- 6-methyl-2-[[(3,4-dimethoxy-2- pyridinyl)methyl]sulfinyl]-1H-benzimidazole-1-yl]methyl ester, disodium salt or phosphoric acid, [6-acetyl-5- methyl-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- 1H-benzimidazole-1-yl]methyl ester, disodium salt.
• Tributylamine (1.7 ml, 7.0 mmol) was added with stirring to a solution of phosphoric acid, 85 per cent (0.24 ml, 3.6 mmol) in ethanol (2 ml). The solvent was evaporated and the residue taken up in methylene chloride (2.5 ml). The organic phase was dried over sodium sulphate, filtered and evaporated.
• Example 2 Preparation of phosphoric acid, [5-carbo methoxy-6-methyl-2-[[(3,4-dimethoxy-2- pyridinyl)methyl]sulfinyl]-1H-benzimidazole-1-yl]methyl ester, disodium salt or phosphoric acid, [6- carbomethoxy-5-methyl-2-[[(3,4-dimethoxy-2- pyridinyl)methyl]sulfinyl]-1H-benzimidazole-1-yl]methyl ester, disodium salt.
• Example I 1 Preparation of 5-acetyl-1-hydroxymethyl-6-methyl-2-[[(3 dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole 6-acetyl-1-hydroxymethyl-5-metyl-2-[[(3,4-dimethoxy-2-p dinyl)methyl]sulfinyl]-1H-benzimidazole To a mixture of 5-acetyl-6-methyl-2-[[(3,4-dimethoxy-2- pyridinyl)methyl]sulfinyl]-1H-benzimidazole (2.00 g,
• compositions containing a compound of the invention as active ingredient are illustrated in the following formulations.
• flavouring agents dissolved in ethanol were added. The mixture was diluted with water to a final volume of 100 ml. Enteric-coated tablets
• a parenteral formulation for intravenous use is provided.
• the active compound was dissolved in water to a final volume of 1000 ml.
• the solution was filtered through a 0.22 ⁇ m filter and immediately dispensed into 10 ml sterile ampoules. The ampoules were sealed. Tablets
• Tablets containing 30 mg of active compound were prepared from the following ingredients: Compound according to Example 3 in Table 3 300 g
• the active compound was mixed with lactose and part of the PVP-XL and granulated with a solution of methyl cellulose and disodium hydrogen phosphate.
• the wet mass was forced through a screen and dried in a fluidized bed dryer. After adding magnesium stearate and the remainder in PVP-XL and mixing, the drug mixture was compressed into tablets with a mean weight of 110 mg, each tablet containing 30 mg of the active compound.
• Suppositories were prepared from the following
• Each suppository contained 40 mg of active compound.
• the active compound mixture was homogenously mixed with Witepsol H-15 at a temperature of 41°C.
• the molten mass was volume filled into pre-fabricated suppository packages to a net weight of 1.84 g. After cooling the packages were heat sealed.
• Each suppository contained 40 mg of active compound.
• the active compound dissolved in 10 ml of sterile water is transferred into 100 ml of normal saline solution for infusion to give a total volume of about 110 ml.
• the solution is administered as an intravenous infusion during a time period of about 30 minutes.
• a syrup containing 1% of active substance was prepared from the following ingredients:
• the active compound was dissolved in water to a final volume of 1000 ml.
• the solution was filtered through a sterile 0.22 ⁇ m filter and aseptically dispensed into 1 ml sterile ampoules. The ampoules were sealed.
• Sterile compound according to Example 2 60 mg Sterile injection vials and stoppers Sterile active compound, 60 mg, was dispensed into 10 ml sterile injection vials. The vials were stoppered with sterile rubberstoppers. The vokale filling operation was performed under aseptic conditions in a sterile production area under vertical laminar flow.
• Test substances suspended in 0.5% buffered (pH 9) methocel, were administered by oral gavage in a volume of 5 ml/kg body weight. After 1 hour, 125 I (300kBq/kg,
• test agent- and placebo- treated animals were assessed with the Mann-Whitney U- test (two-tailed). P ⁇ 0.05 was accepted as significant.
• Table 4 give the test data available for the compounds of the invention.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=20384667

Family Applications (1)

Country Status (25)

Families Citing this family (9)

Family Cites Families (4)

• 1991
  • 1991-12-19 SE SE9103776A patent/SE9103776D0/xx unknown
• 1992
  • 1992-10-06 IS IS4079A patent/IS4079A/is unknown
  • 1992-11-11 TW TW081109053A patent/TW224100B/zh active
  • 1992-11-16 ZA ZA928836A patent/ZA928836B/xx unknown
  • 1992-11-25 YU YU101692A patent/YU101692A/sh unknown
  • 1992-12-07 HR HR921400A patent/HRP921400A2/hr not_active Application Discontinuation
  • 1992-12-08 CA CA002124689A patent/CA2124689A1/en not_active Abandoned
  • 1992-12-08 EP EP93900477A patent/EP0628049A1/en not_active Withdrawn
  • 1992-12-08 KR KR1019940702131A patent/KR940703840A/ko not_active Withdrawn
  • 1992-12-08 SK SK735-94A patent/SK73594A3/sk unknown
  • 1992-12-08 NZ NZ246220A patent/NZ246220A/en unknown
  • 1992-12-08 JP JP5510832A patent/JPH07502503A/ja active Pending
  • 1992-12-08 WO PCT/SE1992/000844 patent/WO1993012124A1/en not_active Application Discontinuation
  • 1992-12-08 FI FI942912A patent/FI942912L/fi not_active Application Discontinuation
  • 1992-12-08 HU HU9401840A patent/HUT68270A/hu unknown
  • 1992-12-08 CZ CZ941467A patent/CZ146794A3/cs unknown
  • 1992-12-08 AU AU31752/93A patent/AU665043B2/en not_active Ceased
  • 1992-12-08 IL IL104025A patent/IL104025A0/xx unknown
  • 1992-12-14 AP APAP/P/1992/000463A patent/AP397A/en active
  • 1992-12-15 MX MX9207269A patent/MX9207269A/es unknown
  • 1992-12-16 MA MA23036A patent/MA22746A1/fr unknown
  • 1992-12-18 CN CN92114364A patent/CN1031827C/zh not_active Expired - Fee Related
  • 1992-12-18 TN TNTNSN92115A patent/TNSN92115A1/fr unknown
  • 1992-12-18 IS IS3960A patent/IS3960A/is unknown
  • 1992-12-18 SI SI19929200402A patent/SI9200402A/sl unknown
• 1994
  • 1994-06-14 NO NO942230A patent/NO942230D0/no unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events